Expertise: Wall Street takes deep dive on Alnylam Pharmaceuticals

Explore expert insights from Wall Street with this upcoming ProResearch article subscriber investment expert. Enhance your investing strategies with ProPicks, our latest offering that outperforms the S&P 500 by up to 700%.Start the new year with up to 50% off, plus 10% off a 2-year subscription with code Study 23, limited to the first 500 quick registrants. To ensure continued access to valuable content like this, step up your investing game with InvestingPro.

In the biopharmaceutical world, Alnylam Pharmaceuticals remains a high-profile company focused on treating serious diseases with RNA interference (RNAi) therapies. The company’s stock (NASDAQ: ALNY ) remains a focus of analysts, who provide the latest insights into its prospects, performance and potential, reflecting a positive view of the industry and its strategic direction confidence.

Product segmentation and clinical trials

Alnylam introduces a dynamic portfolio of FDA/EMA-approved medicines to treat rare diseases and several promising drug candidates in development. The company recently disclosed early data on ALN-TTRsc04, targeting ATTR amyloidosis, which showed promise to support annual dosing, and early data on ALN-KHK, a treatment for type 2 diabetes, showing progress in its pipeline. Zilebesiran, designed to treat high blood pressure, continues to generate buzz, especially with KARDIA-2 Phase II data expected to be released in the first half of 2024, which will explore its effectiveness in combination with standard hypertension medications. The KARDIA-3 study in high-risk patients is expected to begin in early 2024.

The highly anticipated Phase 3 HELIOS-B trial of AMVUTTRA for the treatment of ATTR amyloid cardiomyopathy, with leading endpoints focused on all-cause mortality, is expected to conduct combined Amvuttra/Tafamidis data in the first half of 2024. Alnylam’s strategic partnership with Roche, including substantial upfront payments and potential milestones, reinforces confidence in Alnylam’s technology and pipeline. Management expressed high confidence in the successful results of the HELIOS-B study and plans to submit an sNDA in mid-2024, assuming success. Alnylam will collaborate with Regeneron to provide multi-dose data on ALN-APP and initiate Phase II studies in Alzheimer’s disease and cerebral amyloid angiopathy (CAA).

financial health

Alnylam’s financial position is strong, with a projected cash position of an estimated $2.5 billion, allowing the company to fund its operations and research initiatives. However, the company faces a massive debt load of $1 billion, and investors should pay close attention. As of December 22, 2023, the stock price was US$181.14, and the market value was US$22.654 billion. Financial forecasts for the next few years show that earnings per share (EPS) are expected to improve, turning from a loss in 2022 to positive earnings in 2024. Guidance numbers provided by BMO include earnings per share forecast of $(6.50) in 2022, rising to $(1.67) in 2023 and $0.47 in 2024. Revenue is expected to increase from $1.037 billion in 2022 to $1.773 billion in 2023, but then decline slightly to $1.628 billion in 2024.

Competitive landscape and market trends

Competition in the biopharmaceutical industry remains fierce, with many companies vying for market share in treating similar diseases. Alnylam’s focus on RNAi therapeutics differentiates it from competitors and offers a new way to treat serious diseases. The company has the ability to develop collaboration agreements (such as the one with Roche), provide financial support and validate its technology. Additionally, Alnylam’s expansion into obesity with development candidates targeting the INHBE gene, as well as further growth in hematology, type 2 diabetes and liver disease, may drive future revenue growth. The company’s pipeline expansion is strong and it expects to have nine wholly-owned new drug (IND) applications and six collaborative new drug (IND) applications by the end of 2025.

Legal environment and risks

As with any pharmaceutical company, the regulatory environment continues to present risks to Alnylam. The clinical trial and approval process is unpredictable, and setbacks can seriously affect a company’s prospects. Although Onpattro recently received a complete response letter (CRL) in ATTR-CM, the company remains optimistic about the HELIOS-B trial results and the progress of SubQ ALN-TTRsc04 into Phase 3 trials next year, which may provide a competitive advantage . – ATTR-CM One-year subcutaneous treatment regimen.

Management and Strategy

Alnylam’s leadership has demonstrated strategic foresight by securing valuable partnerships and sustaining a pipeline of near-term catalysts. The company’s recent R&D Day provided additional details about its extrahepatic RNAi program, confirmed timelines for key programs and announced new genetically validated targets, underscoring our commitment to innovation and expanding our therapeutic portfolio. Additionally, advances in conjugate-based extrahepatic delivery and continued innovation in carrier-based hepatic delivery through the reLNP platform enable expansion into oncology with ALN-BCAT targeting HCC, demonstrating the company’s success in many Strategic position in therapeutic areas.

Analyze goals

– Barclays Capital: Overweight rating, price target of $236.00 (as of December 14, 2023).

– BMO Capital Markets Corp.: Outperform rating, price target of $234.00 (as of January 2, 2024), maintaining confidence in the stock, with an estimated market cap of $24.021 billion and total profit potential of 22.3%.

– RBC Capital Markets: Outperform rating, $235.00 price target (as of October 11, 2023).

– Piper Sandler: Overweight rating, price target of $217.00 (as of December 22, 2023).

– HC Wainwright &Co: Buy rating, price target $395.00 (as of November 6, 2023).

– Cantor Fitzgerald: Neutral rating, $165.00 price target (as of December 14, 2023).

bear box

Does Alnylam Pharmaceuticals face significant legal risks?

The regulatory environment for Alnylam is challenging, and the recent CRL for Onpattro in the ATTR-CM highlights the unpredictability of the approval process. Despite a solid safety record and favorable advisory committee votes, such hurdles create uncertainty that could impact future product approvals and the company’s short-term prospects. Other risks may include clinical trial failures or delays, regulatory failures or lower than expected market penetration.

What does the competitive landscape mean for Alnylam’s growth?

Alnylam operates in a highly competitive field, with many players developing treatments for similar conditions. While competition includes other RNAi therapies and traditional therapies, Alnylam’s market share and pricing power may face challenges. The company’s strategic fit will be tested as the product moves toward commercialization, and the current share price exceeds Cantor Fitzgerald’s price target, indicating limited upside potential based on its assessed price.

cow case

Could Upcoming Clinical Trials Boost Alnylam Pharmaceuticals’ Growth?

The company’s pipeline has significant potential, with multiple Investigational New Drug (IND) applications planned for the end of 2025, indicating future growth and diversification of revenue streams. Positive reaffirmations of key clinical trial milestones at recent R&D days provide clarity and confidence in the company’s strategic direction, and positive data from trials such as HELIOS-B can act as an important catalyst, potentially boosting stock performance and solidifying market position. Amvuttra is expected to be used as monotherapy, and potential patients are particularly likely to switch from Tafamidis due to various advantages, including cost, dosing frequency and response rates.

From an analyst perspective, the Phase III HELIOS-B data is expected to be a key catalyst, with an sNDA submission expected by mid-2024 to expand the scope of the treatment. Collaborations with Roche and Regeneron on various clinical programs and a strong pipeline of multiple IND filings planned support the optimistic outlook.

SWOT analysis

strength:

– Robust RNAi therapeutics pipeline including multiple FDA/EMA approved drugs.

– Strategic partnerships with industry leaders such as Roche and Regeneron.

– Sufficient cash position to fund R&D initiatives.

weakness:

– A huge debt load of $1 billion.

– Legal risks, as evidenced by the recent CRL of Onpattro.

– Competition for similar treatments in the biopharmaceutical sector.

Chance:

– More than 9 exclusive IND applications are expected by the end of 2025 for liver indications, central nervous system diseases and other tissues.

– Expand addressable market through successful test results and pipeline progress.

threaten:

– Unpredictable regulatory approval process.

– The biopharmaceutical industry is highly competitive and has great price pressure.

The time range used in this analysis is September to December 2023.

More information about InvestingPro

As we dig deeper into Alnylam Pharmaceuticals’ financial and operational complexities, a few key metrics from InvestingPro stand out. The company’s market capitalization was adjusted to US$24.02 billion, reflecting its position in the biopharmaceutical industry. Despite not turning a profit in the last 12 months, Alnylam’s revenue grew significantly by 79.37% during the same period, demonstrating the company’s expanding business and market reach. Revenue growth was even more pronounced on a quarterly basis, with an impressive 183.96% increase in the third quarter of 2023. This acceleration in revenue growth is a positive sign for investors, who are looking for growth potential in biopharma investments.

While Alnylam has a P/E ratio of -46.90, indicating that the company is not currently profitable, it’s worth noting that six analysts have upgraded earnings for the coming period, indicating optimism about Alnylam’s future financial performance. This alignment with the company’s strategic initiatives and pipeline development can improve financial performance.

InvestingPro Tips also highlights that Alnylam has moderate debt levels, with liquid assets exceeding its short-term liabilities, providing the company with a degree of financial flexibility. Additionally, Alnylam has delivered strong returns over the past five years, which may appeal to long-term investors. However, it’s worth noting that analysts don’t predict that the company will turn a profit this year or pay a dividend to shareholders, which could impact the investment decisions of investors looking for immediate profits or income.

For those interested in learning more about Alnylam Pharmaceuticals’ prospects, InvestingPro has further details. Subscribers can access a range of InvestingPro Tips by visiting InvestingPro’s Alnylam page. Currently, InvestingPro registration is on special sale during the Spring Festival with discounts of up to 50%.Additionally, by using the coupon code Study 23, users can enjoy an additional 10% discount with a 2-year subscription to InvestingPro+.Many other tips are listed in InvestingPro subscribers are fully equipped to make informed investment decisions.